We next performed RNA-ISH analysis of human tumor tissues and ELISA in blood samples from a published cohort of resectable patients with HCC.31 Furthermore, we collected blood samples from patients treated by regorafenib as standard of care (HCC); in addition, we examined the effect of regorafenib on blood CXCL10 levels in a clinical trial in a different disease—AML (NCT03042689). This evidence concerns the gene CXCL10 and acute myeloid leukemia.